Dyslipidemia is a prominent feature of insulin resistance and obesity and may contribute to increased risk of cardiovascular disease. Dyslipidemia associated with these conditions is typically characterized by elevated plasma triglyceride (TG) concentration, low high-density lipoprotein (HDL) cholesterol level, and increased proportion of small, dense, low-density lipoprotein (LDL) particles. It is also now well established that insulin-resistant and type 2 diabetic individuals have elevated levels of TG-rich lipoprotein (TRL) particles and remnants, including intestinally derived apolipoprotein B-48 (apoB-48)–containing TRL, in both the fasted and postprandial states. The latter is of particular clinical importance because these remnant lipoprotein particles may impair endothelial function and may enter and be retained in the subendothelial space of the vascular wall, thus potentially accelerating the development of atherosclerotic lesions.

Indeed, elevated intestinally derived remnant lipoproteins have been associated with increased cardiovascular disease.

It is therefore of considerable clinical interest to better understand the mechanism(s) leading to TRL accumulation so that strategies can be formulated to reduce their plasma levels.

Fasting hypertriglyceridemia in insulin resistance has been attributed largely to apoB-100–containing TG-rich very low-density lipoprotein (VLDL) overproduction and secretion by the liver, with a lesser contribution from impaired VLDL removal. In addition, postprandial lipemia has been well described in insulin-resistant humans and in animal models of insulin resistance. Indeed, in humans, insulin resistance is associated with postprandial elevation of apoB-48–containing TRL particles, and fasting hypertriglyceridemia predicts this abnormal postprandial response.

However, the precise mechanisms underlying this overaccumulation of intestinal lipoproteins in insulin-resistant states are not yet fully understood. To date, studies have focused on the delayed clearance of TRL remnants, attributed to: (1) impaired lipolysis attri-
utable to decreased lipoprotein lipase activity, (2) modified lipoprotein apolipoprotein composition, (3) reduced remnant recognition by hepatic receptors, or (4) an expanded pool of VLDL leading to competition for removal between VLDL and chylomicrons.\(^{13-15}\) Whether exaggerated postprandial lipemia also involves intestinal overproduction of chylomicrons and remnants in addition to a delayed clearance has not been fully investigated, and little information is available regarding the factors that regulate apoB-48–containing lipoprotein production in insulin-resistant humans. We have recently shown that diet-induced insulin resistance in Syrian Golden hamsters is associated with a marked increase in intestinal lipoprotein production rate (PR) in both the fasting and the fed states,\(^{16-18}\) and insulin sensitization partially reversed apoB-48–containing lipoprotein oversecretion.\(^{17,18}\) However, to date, the relevance of these findings to humans is not known, and there is no evidence that insulin resistance is associated with increased intestinal apoB-48–containing lipoprotein particle overproduction in humans. Therefore, the aim of the present study was to determine whether intestinal TRL–apoB-48 production or clearance is perturbed in men with features of hyperinsulinemia and insulin resistance.

**Materials and Methods**

**Subjects**

Fourteen healthy, normoglycemic men, 31 to 60 years of age, with a broad range of body weights (from 64.3 to 134.3 kg), BMIs (from 20.0 to 41.6 kg/m\(^2\)), and waist girth (from 77 to 135 cm) participated in the study. Subjects were included if their total plasma cholesterol was \(<5.5\) mmol/L, HDL cholesterol \(>0.8\) mmol/L, LDL cholesterol \(\leq 4.0\) mmol/L, and TGs \(<4.0\) mmol/L. All participants were non-smokers, and none had a previous history of cardiovascular disease or systemic illness. None had any surgical intervention within 6 months before the studies. No subject was taking medications, and all had a normal 75-g oral glucose tolerance test performed immediately before enrollment in the study. An index of insulin sensitivity was derived from fasting insulin and glucose concentrations using the homeostasis model assessment-insulin resistance (HOMA-IR) method, as described previously.\(^{19,20}\)

The research ethics board of the University Health Network, University of Toronto, approved the study, and all subjects gave written informed consent before their participation.

**Lipoprotein Kinetic Studies**

After a 14-hour overnight fast, an intravenous catheter was inserted into a superficial vein in each forearm: 1 for infusion and 1 for sampling. After the withdrawal of a baseline sample, the subject was instructed to ingest 15 identical hourly volumes of a liquid food supplement called Boost (Mead Johnson Nutritional), each equivalent to one fifteenth of their total daily caloric needs, using the Harris Benedict equation to determine the total energy requirements (based on height, weight, age, and activity factors).\(^{21,22}\) Boost contains 20% of total calories from protein, 62% carbohydrates, and 18% fat (of the total energy derived from fat, 25% was polyunsaturated fat, 65% monounsaturated fat, and 13% saturated fatty acid). Three hours later (at \(\sim 10\) AM), all subjects received a primed constant infusion (10 \(\mu\)mol/kg bolus followed by 10 \(\mu\)mol/kg per hour for 12 hours) of deuterium-labeled leucine\(^{23}\) (\(-[5,5,5-\text{H}]\)-leucine; 98%; Cambridge Isotope Laboratories) to enrich apoB-48 in intracellularly derived lipoprotein particles and to calculate the production and clearance rates of the particles as described previously (see the online supplemental methods, available at http://atvb.ahajournals.org).\(^{23}\)

Blood samples were collected at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 5 hours, 7 hours, 9 hours, 10 hours, 11 hours, and 12 hours into sterile tubes containing 0.1% EDTA and 10 \(\mu\)l preservative (containing 17 \(\mu\)g/ml aprotinin and 0.2 mg sodium azide) and placed immediately on ice.

**Sample Processing, Laboratory Measurements, Analysis of Lipoprotein Production and Clearance Rates, and Statistical Analysis**

Please see the online data supplement, available at http://atvb.ahajournals.org.

**Results**

**Demographic and Biochemical Characteristics of Subjects**

As a method of analyzing the data to determine whether apoB-48 PRs are increased in those with features of insulin resistance, subjects were divided into 2 groups based on their fasting plasma insulin concentration. The second method of data analysis was to examine correlations between apoB-48 PR and indices of insulin resistance, as reported below. By design, subjects in the higher-insulin group (above the median of 60 pmol/L) had a mean (±SEM) insulin level of 128.9±8.9 pmol/L compared with the lower-insulin group, which had a mean insulin of 45.4±4.4 pmol/L (\(P=0.00001\)). Data in the tables are presented separately for these 2 arbitrarily segregated groups of subjects. Subjects with higher fasting plasma insulin concentrations had significantly elevated waist circumference and HOMA-IR compared with those with lower insulin levels (Table 1). BMI and body weight were elevated in the hyperinsulinemic group, but the difference was not significant. Fasting blood glucose and free fatty acid (FFA) levels were not significantly different.

**Plasma and TRL Lipid and Apolipoprotein Concentrations**

Plasma total cholesterol, HDL cholesterol, and LDL cholesterol were not significantly different between individuals with fasting insulin levels above or below the median (Table 2). Fasting TG levels tended to be higher (1.6-fold higher) in the high-insulin group (1.59±0.26 versus low-insulin group 1.09±0.08 mmol/L; \(P=0.121\)), although the difference was not statistically significant. In the fasting state, TRL TGs (TRL-TGs) tended to be higher (1.6-fold) in the high-insulin group and were positively correlated with plasma insulin concentrations (\(r=0.692\); \(P=0.006\)) and HOMA-IR (\(r=0.697\); \(P=0.006\); Table 2). TRL apoB-48 concentrations tended to be higher in the higher versus the lower-insulin group, but the difference was not statistically significant (0.66±0.15 versus 0.39±0.05 mg/dL; \(P=0.15\); Table 2).

**Plasma and TRL-TGs and TRL ApoB-48 Concentrations in Response to Feeding**

TRL-TGs were higher in the higher-insulin group compared with the lower-insulin group throughout the kinetic study (Figure 1A; mean TRL-TGs 1.72±0.10 versus 1.12±0.08 mmol/L; \(P=0.0005\)). As expected, TRL-TGs during feeding were positively correlated with fasting plasma TGs (\(r=0.609\); \(P=0.021\)) and were significantly associated with fasting plasma insulin concentration (\(r=0.890\); \(P<0.001\)) and HOMA-IR (\(r=0.843\); \(P<0.001\)). As can be seen in Figure 1B, no statistically significant difference in steady-state–fed
TABLE 1. Demographic and Biochemical (Fasting Plasma Metabolites, Hormone, and Lipids) Characteristics of Subjects With Insulin Above and Below the Median

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (years)</th>
<th>Weight (kg)</th>
<th>BMI (kg/m²)</th>
<th>Waist (cm)</th>
<th>FFA (mmol/L)</th>
<th>Glucose (mmol/L)</th>
<th>Insulin (pmol/L)</th>
<th>HOMA-IR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin &gt;60 pmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>46</td>
<td>95.0</td>
<td>32.8</td>
<td>112</td>
<td>0.45</td>
<td>5.1</td>
<td>160.2</td>
<td>6.05</td>
</tr>
<tr>
<td>2</td>
<td>59</td>
<td>98.0</td>
<td>30.6</td>
<td>108</td>
<td>0.33</td>
<td>5.3</td>
<td>151.0</td>
<td>5.93</td>
</tr>
<tr>
<td>3</td>
<td>55</td>
<td>106.5</td>
<td>29.8</td>
<td>108</td>
<td>0.23</td>
<td>5.7</td>
<td>123.0</td>
<td>5.19</td>
</tr>
<tr>
<td>4</td>
<td>60</td>
<td>83.2</td>
<td>28.4</td>
<td>97</td>
<td>0.27</td>
<td>4.7</td>
<td>120.0</td>
<td>4.18</td>
</tr>
<tr>
<td>5</td>
<td>31</td>
<td>112.5</td>
<td>33.6</td>
<td>111</td>
<td>0.42</td>
<td>4.9</td>
<td>114.0</td>
<td>4.14</td>
</tr>
<tr>
<td>6</td>
<td>40</td>
<td>123.5</td>
<td>39.0</td>
<td>135</td>
<td>0.50</td>
<td>5.5</td>
<td>105.0</td>
<td>4.28</td>
</tr>
<tr>
<td>Mean±SEM</td>
<td>48.5±4.7</td>
<td>103.1±5.8</td>
<td>32.4±1.5</td>
<td>112±5</td>
<td>0.37±0.04</td>
<td>5.2±0.1</td>
<td>128.9±8.9</td>
<td>4.96±0.36</td>
</tr>
<tr>
<td>Insulin &lt;60 pmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>50</td>
<td>66.0</td>
<td>25.1</td>
<td>86</td>
<td>0.38</td>
<td>5.1</td>
<td>60.0</td>
<td>2.27</td>
</tr>
<tr>
<td>2</td>
<td>39</td>
<td>134.3</td>
<td>41.6</td>
<td>127</td>
<td>0.37</td>
<td>4.0</td>
<td>59.0</td>
<td>1.75</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>76.3</td>
<td>25.5</td>
<td>92</td>
<td>0.34</td>
<td>5.6</td>
<td>51.0</td>
<td>2.12</td>
</tr>
<tr>
<td>4</td>
<td>51</td>
<td>67.0</td>
<td>21.8</td>
<td>84</td>
<td>0.17</td>
<td>4.5</td>
<td>46.2</td>
<td>1.54</td>
</tr>
<tr>
<td>5</td>
<td>42</td>
<td>76.5</td>
<td>25.5</td>
<td>86</td>
<td>0.49</td>
<td>4.7</td>
<td>43.2</td>
<td>1.50</td>
</tr>
<tr>
<td>6</td>
<td>41</td>
<td>64.3</td>
<td>20.0</td>
<td>77</td>
<td>0.39</td>
<td>5.1</td>
<td>14.4</td>
<td>1.56</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>82.5</td>
<td>24.7</td>
<td>92</td>
<td>0.40</td>
<td>4.8</td>
<td>14.4</td>
<td>1.47</td>
</tr>
<tr>
<td>8</td>
<td>50</td>
<td>79.0</td>
<td>24.3</td>
<td>83</td>
<td>0.54</td>
<td>4.5</td>
<td>21.0</td>
<td>0.7</td>
</tr>
<tr>
<td>Mean±SEM</td>
<td>47.6±2.3</td>
<td>80.7±8</td>
<td>26.1±2.3</td>
<td>91±5</td>
<td>0.38±0.04</td>
<td>4.8±0.2</td>
<td>45.4±4.4</td>
<td>1.61±0.17</td>
</tr>
<tr>
<td>P value</td>
<td>0.859</td>
<td>0.056</td>
<td>0.058</td>
<td>0.019</td>
<td>0.77</td>
<td>0.11</td>
<td>&lt;0.00001</td>
<td>&lt;0.00001</td>
</tr>
</tbody>
</table>

The 14 subjects were divided into 2 groups based on their fasting insulin plasma levels. P values are by unpaired t test.

Discussion

In the present study, apoB-48 PRs were found to be positively correlated with fasting insulin concentrations, despite great heterogeneity in apoB-48 kinetic parameters, particularly among the obese subjects. We also demonstrated a higher PR of intestinally derived apoB-48–containing lipoprotein particles in men with hyperinsulinemia and insulin resistance compared with those with lower insulin levels and greater insulin sensitivity. The clearance of apoB-48–containing lipoproteins in those with hyperinsulinemia and insulin resistance tended to be higher than in those with normoinsulinemia, although this difference was not significant, and there was no significant association within apoB-48 fractional clearance rate (FCR) and either fasting insulin levels (r=0.295; P=0.306) or HOMA-IR (r=0.314 and P=0.273, respectively).

Effects of Fasting Plasma Insulin Concentration and HOMA-IR on Intestinal Lipoprotein Production and Clearance Rates

The influence of fasting plasma insulin concentration on apoB-48–containing TRL metabolism during constant fat feeding was next examined by kinetic studies in patients using a 12-hour primed constant infusion of a stable isotope as described in the Methods. The clearance of TRL–apoB-48 tended to be higher in subjects with high-versus low-insulin, but the difference was not statistically significant (higher-insulin group 4.83±1.27 versus lower-insulin group 3.23±0.84 pool per day; P=0.29; Table 2; Figure 2B). However, TRL–apoB-48 PR was significantly higher in the group with higher insulin levels and HOMA-IR score (Table 2; Figure 2A).

Correlation of TRL–Apo-B48 PR With Plasma Insulin and HOMA-IR

TRL–apoB-48 PR was positively correlated with fasting insulin concentration (r=0.558; P=0.038) and tended to be correlated with HOMA-IR index (r=0.515; P=0.059; Table 2). Because subjects within the higher-insulin group were overweight compared with those with lower insulin, we performed univariate ANOVAs to test whether body weight, BMI, and waist may have contributed to the effect of insulin level on TRL–apoB-48 PR. However, none of these parameters were found to influence our results (P=0.219, P=0.426, and P=0.340, respectively). There was no association between TRL–apoB-48 fractional clearance rate (FCR) and either fasting insulin levels (r=0.295; P=0.306) or HOMA-IR (r=0.314 and P=0.273, respectively).
Correlation with HOMA-IR (P as occurs with abdominal obesity and insulin resistance. In those with even mild fasting hypertriglyceridemia, such resulting in greater impairment in chylomicron clearance by lipoprotein lipase with endogenous VLDL, derived from the rapidly ingested fat load compete for load. In that setting, the large influx of chylomicrons non–steady-state condition after ingestion of an oral fat meal. In the present study, we assessed TRL apoB-48 production and clearance at steady-state plasma TRL–apoB-48 and TRL-TG concentrations induced by repeated, small-quantity liquid meals. Different findings between the studies have labeled the TG moiety of lipoprotein particles and examined TRL-TG clearance or modeled the area under the curve of plasma apoB-48 or plasma TG concentration after an oral fat load. TGs are contained in both intestinally derived as well as hepatically derived plasma lipoproteins, and there is no way of distinguishing the suggested defective catabolism of intestinally derived TRL and remnant lipoprotein TG in insulin-resistant and obese individuals. However, the design of those studies differed from ours in a number of respects, not least of which was that they examined TRL particle clearance in a non–steady-state condition after ingestion of an oral fat load. In that setting, the large influx of chylomicrons derived from the rapidly ingested fat load compete for clearance by lipoprotein lipase with endogenous VLDL, resulting in greater impairment in chylomicron clearance in those with even mild fasting hypertriglyceridemia, such as occurs with abdominal obesity and insulin resistance. In

**TABLE 2. Plasma Lipids and TRL TG and ApoB Concentrations in the Fasted State and Postprandial TRL ApoB-48 PR and FCR in Subjects With Insulin Above and Below the Median**

<table>
<thead>
<tr>
<th>Subject</th>
<th>Plasma Total Cholesterol (mmol/L)</th>
<th>Plasma HDL-c (mmol/L)</th>
<th>Plasma LDL-c (mmol/L)</th>
<th>Plasma TG (mmol/L)</th>
<th>TRL TG (mmol/L)</th>
<th>TRL ApoB (mg/dL)</th>
<th>TRL ApoB-48 PR (mg/kg per day)</th>
<th>TRL ApoB-48 FCR (pool per day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin &gt;60 pmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4.23</td>
<td>1.09</td>
<td>1.94</td>
<td>2.69</td>
<td>1.64</td>
<td>16.7</td>
<td>0.92</td>
<td>1.30</td>
</tr>
<tr>
<td>2</td>
<td>5.42</td>
<td>0.97</td>
<td>3.26</td>
<td>1.96</td>
<td>1.49</td>
<td>16.0</td>
<td>0.61</td>
<td>2.85</td>
</tr>
<tr>
<td>3</td>
<td>4.09</td>
<td>0.95</td>
<td>2.46</td>
<td>1.31</td>
<td>0.70</td>
<td>7.0</td>
<td>0.36</td>
<td>0.27</td>
</tr>
<tr>
<td>4</td>
<td>4.31</td>
<td>0.97</td>
<td>2.92</td>
<td>0.88</td>
<td>0.44</td>
<td>8.2</td>
<td>0.47</td>
<td>2.75</td>
</tr>
<tr>
<td>5</td>
<td>4.76</td>
<td>0.89</td>
<td>3.25</td>
<td>1.21</td>
<td>0.74</td>
<td>12.2</td>
<td>1.28</td>
<td>1.73</td>
</tr>
<tr>
<td>6</td>
<td>4.45</td>
<td>1.06</td>
<td>2.96</td>
<td>1.49</td>
<td>1.11</td>
<td>10.5</td>
<td>0.33</td>
<td>1.50</td>
</tr>
<tr>
<td>Mean± SEM</td>
<td>4.54±0.20</td>
<td>0.99±0.03</td>
<td>2.90±0.20</td>
<td>1.59±0.26</td>
<td>1.05±0.22</td>
<td>11.8±1.6</td>
<td>0.68±0.15</td>
<td>1.73±0.39</td>
</tr>
<tr>
<td>Insulin &lt;60 pmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4.21</td>
<td>1.02</td>
<td>2.52</td>
<td>1.38</td>
<td>0.78</td>
<td>14.1</td>
<td>0.31</td>
<td>1.40</td>
</tr>
<tr>
<td>2</td>
<td>4.79</td>
<td>1.25</td>
<td>2.70</td>
<td>1.48</td>
<td>0.81</td>
<td>16.1</td>
<td>0.45</td>
<td>0.43</td>
</tr>
<tr>
<td>3</td>
<td>4.81</td>
<td>1.09</td>
<td>3.35</td>
<td>0.97</td>
<td>0.70</td>
<td>9.4</td>
<td>0.26</td>
<td>0.71</td>
</tr>
<tr>
<td>4</td>
<td>4.25</td>
<td>0.94</td>
<td>2.50</td>
<td>1.09</td>
<td>0.69</td>
<td>14.1</td>
<td>0.30</td>
<td>0.76</td>
</tr>
<tr>
<td>5</td>
<td>3.85</td>
<td>1.05</td>
<td>2.32</td>
<td>0.96</td>
<td>0.58</td>
<td>8.3</td>
<td>0.24</td>
<td>0.71</td>
</tr>
<tr>
<td>6</td>
<td>3.52</td>
<td>0.89</td>
<td>2.07</td>
<td>0.98</td>
<td>0.74</td>
<td>12.1</td>
<td>0.57</td>
<td>0.85</td>
</tr>
<tr>
<td>7</td>
<td>4.76</td>
<td>1.57</td>
<td>2.94</td>
<td>0.74</td>
<td>0.52</td>
<td>10.5</td>
<td>0.45</td>
<td>1.51</td>
</tr>
<tr>
<td>8</td>
<td>5.59</td>
<td>1.16</td>
<td>4.04</td>
<td>1.13</td>
<td>0.55</td>
<td>7.7</td>
<td>0.55</td>
<td>0.68</td>
</tr>
<tr>
<td>Mean± SEM</td>
<td>4.47±0.23</td>
<td>1.12±0.08</td>
<td>2.81±0.22</td>
<td>1.09±0.08</td>
<td>0.57±0.04</td>
<td>11.5±1.1</td>
<td>0.39±0.05</td>
<td>0.88±0.13</td>
</tr>
</tbody>
</table>

*p* (High vs low insulin levels) = 0.0001; and for TRL apoB-48: *p* = 0.0288. Subjects (n=14) were divided into 2 groups based on fasting insulin plasma levels. *p* values are by unpaired *t* test.

HDL-c indicates HDL cholesterol; LDL-c, LDL cholesterol; nd, XXX.

**Figure 1.** TRL-TG and TRL apoB-48 concentrations over the time course of the kinetic study. TRL-TG (A) and TRL apoB-48 (B) were measured throughout the 15-hour lipoprotein turnover study in subjects with low (<60 pmol/L; □: n=8) or high (>60 pmol/L; ■: n=6) insulin levels. Time 0 hours was fasting, immediately before starting hourly ingestion of liquid formula as described in methods. Analysis of the kinetics of apoB-48 was performed between 3 and 15 hours (ie, over a 12-hour period). Values are mean±SEM for each group. Asterisks indicate difference between high- and low-insulin groups for each time point: *p*<0.005 and **p*<0.001 as analyzed by ANOVA (the overall significance over the time being achieved for TRL-TG: *p*<0.0001; and for TRL apoB-48: *p*<0.0288).
origin of TGs by this in vivo methodology. In the present study, we used a primed continuous infusion of deuterated leucine to label the apolipoprotein (apoB-48) moiety of the intestinally derived lipoprotein particles, allowing us to examine apoB-48 particle clearance rather than TRL-TG clearance. Others have used different approaches such as the measurement of \(^{13}\)CO\(_2\) appearance in breath after ingestion of a labeled chylomicron-like emulsion, which requires not only uptake of TRL-TG and remnant TG by the liver but also, and different from our method, subsequent metabolism of hydrolyzed fatty acids.\(^{29,32}\) Using this method, Watts et al\(^{28}\) failed to find a significant correlation between chylomicron remnant clearance and HOMA-IR in obese men. Studies performed using diabetic rats showed delayed clearance attributable to particle compositional changes with no change in apoB-48 concentration.\(^{29,30}\) Our study by no means negates the finding that chylomicron and chylomicron remnant clearance is delayed after ingestion of a high-fat meal in those with even mild degrees of fasting hypertriglyceridemia, such as occurs in individuals with insulin resistance and type 2 diabetes. The fact that we did not demonstrate a defective clearance of apoB-48-containing lipoproteins in the present study may relate to the slow and modest rate of fat delivery to the intestine with frequent small liquid formula ingestion, which perhaps was insufficient to impair the clearance from the circulation of intestinally derived lipoproteins in those with hyperinsulinemia/insulin resistance. To our knowledge, PR of apoB-48-containing TRL has not been assessed directly in insulin-resistance states in humans to date, and our results represent the first human data to demonstrate higher apoB-48–TRL PRs in hyperinsulinemic individuals. We suggest that overproduction of TRL–apoB-48 in hyperinsulinemia may be an important contributor to postprandial hyperlipidemia in these conditions and may be an important cause of the accumulation of remnant lipoproteins even in the fasted state. This does not necessarily imply that it is the lipids secreted from the intestine per se that contribute directly to the hyperlipidemia of insulin-resistant states. An equally plausible explanation is that the increased numbers of circulating intestinally derived lipoprotein particles that result from higher PRs compete with hepatically derived lipoproteins for clearance mechanisms that become saturated postprandially, thereby impairing their removal and resulting in accumulation of lipoprotein particles of both hepatic and intestinal origin. The relative contributions of overproduction and defective clearance of intestinally derived lipoproteins to postprandial lipemia in insulin-resistant states is currently not known.

The volume of the liquid formula administered to maintain a constant fed state during the lipoprotein turnover study was adjusted for height, weight, and activity factors. Previous apoB-48 turnover studies performed in the constant fed state have also calculated and adjusted calorie/fat intake during the study based on the usual daily intake requirement of the subjects\(^{31,32}\) or using the Harris Benedict equation\(^{20,21}\) as we did. This allows us to study intestinal lipoprotein turnover during a fed state that is stimulated to match the daily caloric intake of each study participant, making it closer to that subject’s “normal” physiology. Consequently, the total calorie and fat content ingested by the more obese hyperinsulinemic subjects was greater than that ingested by those with normoinsulinemia. Although we cannot exclude the possibility that this difference may have contributed to the observed differences in apoB-48 PRs between hyperinsulinemic and normoinsulinemic individuals, the caloric intake values and fat content of ingested liquid supplements were not correlated with fed TRL-TG levels \((r=0.468; P=0.091)\), TRL apoB-48 PR \((r=0.024; P=0.935)\), or TRL apoB-48 FCR \((r=0.033; P=0.910)\). Covariance analysis indicated that the feeding did not significantly influence the effect of insulin levels on any of the study parameters except the anticipated body weight, waist, and body weight.

The present study does not address the cellular mechanisms that underlie the overproduction of lipoproteins by the intestine in hyperinsulinemic, insulin-resistant humans. Nevertheless, previous studies from our group and those of others using animal models of insulin resistance provide important clues regarding potential mechanisms that may also be applicable to humans. For instance, we have reported that oversecretion of apoB-48–containing lipoprotein in fructose-fed insulin-resistant Syrian Golden

---

**Figure 2.** TRL apoB-48 production and FCRs in subjects with high- vs low-insulin levels or high vs low HOMA-IR. ApoB-48 PR (A) and FCR (B) were determined at steady-state in subjects with low (<60 pmol/L) insulin levels and HOMA-IR (<2.3; n = 8) or high (> 60 pmol/L) insulin levels and HOMA-IR (> 2.3; n = 6).

![Figure 2](image-url)
hamsters in both the fasted and fed states is associated with enhanced intracellular stability of nascent apoB-48 in cultured primary enterocytes derived from these animals. Moreover, this is paralleled by increased de novo lipogenesis in enterocytes. Several studies in humans have suggested that lipogenesis in the hepatocyte is increased in insulin resistance and contributes to the overproduction of VLDL TG. It is tempting to speculate that increased intestinal de novo lipogenesis may also play a role in enterocytes with oleic acid leads to stimulation of intestinal apoB-48-containing particle production. We have shown that an acute elevation of plasma FFAs in hamsters markedly increased the basal intestinal apoB-48 PR. Although fasting FFA plasma levels were not significantly different in subjects with higher and lower insulin concentrations in the present study, fasting FFA concentrations are not a sensitive measure of total FFA flux from adipose tissue to liver. Further studies are required to evaluate whether elevated plasma FFAs drive intestinal lipoprotein production in humans, as has been demonstrated for hepatic VLDL secretion.

We have shown that intestinal lipid synthesis and transfer to lipoprotein particles is increased in insulin-resistant hamsters, at least in part via increased MTP mass and activity and enhanced lipoprotein assembly and secretion. MTP has also been shown to be increased in diabetic rats, New Zealand rabbit, and the desert gerbil Psammomys obesus. In addition, humans carrying a common MTP gene polymorphism leading to increased MTP expression were found to have elevated accumulation of small apoB-48-containing lipoproteins in the postprandial state. Along the same line, Lundahl et al have shown that polymorphism in the MTP promoter leading to increased transcriptional activity of the gene was associated with increased apoB-48 in the small TRL fraction after a fat meal. These results indicate that MTP polymorphisms may be linked to the generation of small TRL apoB-48-containing lipoproteins in the fasted state rather than in the fed state. Elevated FFA flux from adipose tissue to the liver in insulin-resistant states is considered to play an important role in diabetic dyslipidemia. Insulin resistance–associated increased FFA flux is known to drive hepatic VLDL assembly and secretion. FFAs stimulate the hepatic synthesis and secretion of VLDL TG in vitro in HepG2 cells and cultured rat hepatocytes and in humans. Guo et al have recently shown that ex vivo incubation of hamster enterocytes with oleic acid leads to stimulation of intestinal apoB-48-containing particle production. We have shown that an acute elevation of plasma FFAs in hamsters markedly increased the basal intestinal apoB-48 PR. Although fasting FFA plasma levels were not significantly different in subjects with higher and lower insulin concentrations in the present study, fasting FFA concentrations are not a sensitive measure of total FFA flux from adipose tissue to liver. Further studies are required to evaluate whether elevated plasma FFAs drive intestinal lipoprotein production in humans, as has been demonstrated for hepatic VLDL secretion.

In conclusion, the present report provides evidence that increased production of apoB-48 is characteristic of hyperinsulinemic men. Further studies are needed to explore the mechanisms underlying the increased production of intestinal lipoproteins in insulin-resistant states and to better determine the contribution of intestinal lipoproteins to atherosclerosis in this population.

Acknowledgments
This work was supported by funding from the Canadian Institutes for Health Research (MOP-43839). G.F.L. holds a Canada Research Chair in Diabetes and is a career investigator of the Heart and Stroke Foundation of Canada. B.L. holds a Canada Research Chair in Diabetes and is a career investigator of the Heart and Stroke Foundation of Canada. We are indebted to Patricia Harley, RN, for her assistance with subject recruitment and conducting the clinical protocol.

References
Abp-48 Overproduction and Insulin Resistance

Duez et al.


Hyperinsulinemia Is Associated With Increased Production Rate of Intestinal Apolipoprotein B-48-Containing Lipoproteins in Humans
Hélène Duez, Benoît Lamarche, Kristine D. Uffelman, René Valero, Jeffrey S. Cohn and Gary F. Lewis
Online Data Supplement

Sample Processing

Plasma was separated from blood samples, within 2 hours, in a refrigerated centrifuge at 2000 rpm for 15 min at 4º C. Triglyceride-rich lipoproteins (TRL) were isolated at each time point at d=1.006 for 16 hrs, 39,000 rpm at 12º C. Plasma IDL, LDL, and HDL were isolated by sequential ultracentrifugation, dialyzed and frozen for lipid and apolipoprotein analyses. Protein in the TRL fraction was determined by the method of Lowry and approximately 1000μg of protein were delipidated using methanol/diethyl ether to separate TRL lipids from protein. Delipidated proteins were separated by preparative 3.3% SDS-PAGE, stained with Coomassie R-250, destained and gel bands containing apoB-48 were excised and placed into 1.5 ml glass vials (Chromatographic Specialties Inc, Brockville, Ontario, Canada) for further processing. ApoB-48 gel slices were hydrolysed and amino acids were purified by cation exchange chromatography before being derivatized to allow for the determination of plasma leucine isotopic enrichment, as previously described. Enrichment of samples with deuterium-labeled leucine was measured by gas chromatography/mass spectrometry (Agilent 5973 GC/MS, Agilent Technologies Canada Inc, Mississauga, Ontario, Canada) using negative chemical ionization and methane as the moderator gas as previously described. Selective ion monitoring at m/z =352 and 349 (ionic species corresponding to derivatized deuterium-labeled and derivatized non-deuterium-labeled leucine, respectively) was performed, and tracer-to-tracee ratios calculated from isotopic ratios for each sample according to the formula derived by Cobelli et al. (a representative curve is presented in Figure 2 of this manuscript). Tracer-to-tracee ratios were corrected for
background leucine in gel slices (i.e., trace amounts of leucine introduced during the amino acid purification and derivitization procedures) by estimating the amount of leucine in processed blank gel slices relative to the norleucine internal standard.

**Laboratory Measurements**

Triglycerides were measured using an enzymatic colorimetric kit (Roche Diagnostics, Mannheim, Germany) in which free glycerol was eliminated in a preliminary reaction, the TG hydrolysed and the liberated glycerol measured. Cholesterol was determined using the CHOD-PAP enzymatic colorimetric kit (Roche Diagnostics, Mannheim, Germany). FFAs were determined with the NEFA colorimetric method (Wako Industrials, Osaka, Japan). Plasma insulin concentrations were assayed by radioimmunassay using a human specific insulin kit (Linco Research, St Louis, MO, USA). Glucose was measured enzymatically using a Beckman Glucose Analyzer II (Beckman Instruments Corporation, Fullerton, CA). Total apoB in plasma and TRL was measured by electroimmunoassay as previously described. ApoB-48 mass in the TRL fraction was quantified using analytical SDS-PAGE as previously described. Briefly 100 μg TRL were delipidated and the precipitate dissolved overnight in sample buffer (0.05 M Tris-HCl, pH 6.8, 2% SDS, 2% 2-mercaptoethanol). An LDL standard (d=1.030–1.040) was also delipidated and treated in the same fashion as the TRL samples. Samples and standard dilutions were then run on 4-20% SDS-PAGE, stained and destained. Stained apoB-48 bands were scanned with a UMAX Image Scanner (Amersham Biosciences, Uppsala, Sweden) and the density of TRL bands were compared to known concentrations of LDL standard to give the mass of the apoB-100
and apoB-48 in TRL fractions. The coefficient of variation for the apoB mass assay was 7%.

**Analysis of lipoprotein production and clearance rates**

Stable isotope enrichment curves for apoB-48 were fitted to a three compartment model using SAAM II computer software (SAAM II institute, WA). Compartment 1 represented the plasma amino acids. Compartment 2 was an intracellular delay compartment, which accounts for the synthesis, assembly and secretion of apolipoproteins and compartment 3 represented circulating plasma lipoproteins. In those subjects where the TRL apoB-48 tracer data attained a plateau, we used this value as a measure of the precursor pool enrichment. In individuals among whom apoB-48 enrichment did not reach plateau (n=1), we let the model define the maximal enrichment rate. Each subject was in steady state with respect to apoB-48 concentrations so FCR (fractional clearance rate) was equivalent to fractional synthetic rate. Kinetic parameters were derived by analyzing individual enrichment curves and only those in which the cv for apoB-48 modeling was <25% were included.

Production rates were calculated using the FCR of TRL apoB-48 multiplied by pool size measured over the 12 hours of the study per kg body weight where pool size = average plasma concentration (mg/dl) between t3hr and t12h of the kinetic x plasma volume (0.045 liter/kg).

**Statistics**

Results are presented as mean ± SEM. Unpaired t-tests were used to compare patients with low vs high insulin levels or HOMA-IR score. A penalty factor was applied when test for homogeneity of variance gave a p-value greater than 0.05, so that the provided p-
values were from t-test not assuming equal variance (analyzed with the SPSS version13 software). Pearson correlation coefficients were determined to test the association between insulin levels and parameters of interest. Univariate analysis of variance (ANCOVA) were used to test the contribution of different parameters on the effect of insulin levels on TRL apoB-48 production and clearance rates. ANOVA was used to analyse TRL-TG and TRL-apoB-48 increase over the time. All analyses were performed with the SPSS version13. For all of the analyses, a p value < 0.05 was considered significant.

References


